DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for retinal detachment — screening already-approved drugs against its 20-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleRetinal detachment maps to a 20-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for retinal detachment is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
collagen type II alpha 1 chain (COL2A1) — COL2A1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet p33drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5NIR · 1.74 Å · ligand 3,6,9,12,15,18-HEXAOXAICOSANE-1,20-DIOL (P33). Experimental structure, not a prediction.
What the evidence adds up to
A 2013 review of retinal detachment surgery notes that oral fluoroquinolones may be associated with onset of retinal detachment, but the clinical relevance of this correlation is uncertain and the finding has not been replicated in subsequent studies. Pars plana vitrectomy continues to show efficacy as a primary treatment, especially in pseudophakic patients. For macula-on retinal detachment, scheduling surgery after a short time delay is not necessarily deleterious and may be beneficial. Bioerodible scleral buckling materials and artificial vitreous substitutes are under investigation.
A 1933 paper states that the function of a reattached retina is almost as complex a problem as the function of the normal retina, and that considerable work by physiologists, psychologists and ophthalmologists will be required to define how well a reattached retina functions after it has been detached for some time. The author notes that in cases of partial but progressive detachment, even an anatomic cure or reattachment without any return of function is a gain. A 1981 communication reports that reapplication of the retina is now very often achieved immediately, repeated intervention has become less common, and operative methods less aggressive. It recalls the importance of early diagnosis and prophylactic measures.
A 1963 report states that during the preceding decade there had been outstanding progress in retinal-detachment surgery, with steadily improving surgical results. It argues that every case of idiopathic retinal detachment should be treated surgically, and that the frequency with which the fellow eye becomes similarly affected is a strong argument for advising operation upon all retinal detachments except those associated with vascular anomalies or uveal inflammation.
No drug is mentioned in these abstracts as a treatment for retinal detachment. The 2013 review mentions a possible association with fluoroquinolones but does not claim efficacy for any drug. What remains missing is a scientific solution to the problem of how well a reattached retina functions after detachment, which the 1933 paper notes will require considerable time and adequate clinical material to resolve.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Ophthalmology · 2013 · 74 citations
Update on retinal detachment surgery
AbstractPURPOSE OF REVIEW: Update on controversies in the surgical management of rhegmatogenous retinal detachment. RECENT FINDINGS: There are multiple new reports regarding the development and management of retinal detachment. Current use of oral fluoroquinolones may be associated with onset of retinal detachment, although the clinical relevance of this correlation is uncertain at this time and the finding has not been replicated in subsequent studies. Pars plana vitrectomy (PPV) continues to demonstrate efficacy as a primary treatment for retinal detachment, especially in pseudophakic patients. In many patients with macula-on retinal detachment, scheduling surgery after a short time delay is not necessarily deleterious and may actually be beneficial. Novel surgical tools, including bioerodible scleral buckling materials and artificial vitreous substitutes, are being investigated. SUMMARY: Retinal detachment remains an important cause of visual loss. Although current surgical techniques demonstrate high rates of anatomic and visual success, further advances will probably benefit patients with retinal detachment.
AbstractFirst, I wish to apologize for the presumptuousness of the title of this paper. I am fully aware of the fact that the function of the reattached retina is almost as complex a problem as the function of the normal retina. It will therefore require considerable work on the part of physiologists, psychologists and ophthalmologists to define exactly how well a reattached retina functions after it has been detached for some time. Until the problem of the function of the reattached retina is solved scientifically—which will take considerable time because of the relative scarcity of adequate material—there is need for a plausible, workable idea in regard the probable functional outcome of an operation for retinal detachment before it can be recommended to the patient. It is true that in cases of partial but progressive detachment, even an anatomic cure or a reattachment without any return of function is a gain.
Klinische Monatsblätter für Augenheilkunde · 1981 · 0 citations
Le décollement de la rétine
AbstractOver the last few years there has been a further increase in the surgical treatment of the retinal detachment. Reapplication of the retina is now very often achieved immediately. Repeated intervention has become less common and operative methods less aggressive. This communication aims to give an idea of present concepts in the treatment of retinal detachment and to explain some surgical attitudes. It also recalls the importance of early diagnosis, as well as the examination methods and the prophylactic measures generally used. Some new ideas on the etiology of retinal detachment are also discussed.
New England Journal of Medicine · 1963 · 0 citations
Progress in Ophthalmic Surgery
AbstractRetinaDuring the past decade there has been outstanding progress in retinal-detachment surgery. Although all problems have not been solved the surgical results are steadily improving. In the light of these operative successes, every case of idiopathic retinal detachment should be treated surgically. Furthermore, the frequency with which the fellow eye becomes similarly affected is a strong argument for advising operation upon all retinal detachments except those associated with vascular anomalies or uveal inflammation. Even in the presence of these conditions surgery may have to be considered.The basic principles and objectives for successful reapposition of the retina were slowly . . .
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
